Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and are Targetable by BET Bromodomain Inhibition.

Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE.

Cancer Res. 2019 Jan 10. pii: canres.1888.2018. doi: 10.1158/0008-5472.CAN-18-1888. [Epub ahead of print]

PMID:
30630822
2.

IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation.

Park SM, Cho H, Thornton AM, Barlowe TS, Chou T, Chhangawala S, Fairchild L, Taggart J, Chow A, Schurer A, Gruet A, Witkin MD, Kim JH, Shevach EM, Krivtsov A, Armstrong SA, Leslie C, Kharas MG.

Cell Stem Cell. 2019 Jan 3;24(1):153-165.e7. doi: 10.1016/j.stem.2018.10.016. Epub 2018 Nov 21.

PMID:
30472158
3.

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.

Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, Vakoc CR, Armstrong SA.

Elife. 2018 Nov 15;7. pii: e41305. doi: 10.7554/eLife.41305.

4.

Improved potency and reduced toxicity of the antifungal peptoid AEC5 through submonomer modification.

Middleton MP, Armstrong SA, Bicker KL.

Bioorg Med Chem Lett. 2018 Dec 1;28(22):3514-3519. doi: 10.1016/j.bmcl.2018.10.001. Epub 2018 Oct 3.

PMID:
30297282
5.

HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.

Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, Phuc Khoa LT, Jang Y, Cai S, Witkin M, Koche R, Ge K, Dressler GR, Levine RL, Armstrong SA, Dou Y, Hess JL.

Cancer Cell. 2018 Oct 8;34(4):643-658.e5. doi: 10.1016/j.ccell.2018.08.018. Epub 2018 Sep 27.

PMID:
30270123
6.

Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras.

Chu SH, Song EJ, Chabon JR, Minehart J, Matovina CN, Makofske JL, Frank ES, Ross K, Koche RP, Feng Z, Xu H, Krivtsov A, Nussenzweig A, Armstrong SA.

Blood Adv. 2018 Oct 9;2(19):2478-2490. doi: 10.1182/bloodadvances.2018021592.

7.

Location, Location, Location: Mutant NPM1c Cytoplasmic Localization Is Required to Maintain Stem Cell Genes in AML.

Uckelmann HJ, Armstrong SA, Stone RM.

Cancer Cell. 2018 Sep 10;34(3):355-357. doi: 10.1016/j.ccell.2018.08.013.

PMID:
30205041
8.

Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.

Hemming ML, Lawlor MA, Zeid R, Lesluyes T, Fletcher JA, Raut CP, Sicinska ET, Chibon F, Armstrong SA, Demetri GD, Bradner JE.

Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5746-E5755. doi: 10.1073/pnas.1802079115. Epub 2018 Jun 4.

9.

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, Daigle SR, Waters NJ, Suttle AB, Clawson A, Pollock R, Krivtsov A, Armstrong SA, DiMartino J, Hedrick E, Löwenberg B, Tallman MS.

Blood. 2018 Jun 14;131(24):2661-2669. doi: 10.1182/blood-2017-12-818948. Epub 2018 May 3.

PMID:
29724899
10.

A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response.

Hoshii T, Cifani P, Feng Z, Huang CH, Koche R, Chen CW, Delaney CD, Lowe SW, Kentsis A, Armstrong SA.

Cell. 2018 Feb 22;172(5):1007-1021.e17. doi: 10.1016/j.cell.2018.01.032.

PMID:
29474905
11.

LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.

Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY Jr, Koche RP, Armstrong SA.

Blood. 2018 Apr 12;131(15):1730-1742. doi: 10.1182/blood-2017-09-807024. Epub 2018 Feb 16.

PMID:
29453291
12.

MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.

Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan V, Bhola P, O'Donnell C, Spitzer B, Stutzke C, Lavallée VP, Hébert J, Krivtsov AV, Melnick A, Paietta EM, Tallman MS, Letai A, Sauvageau G, Pouliot G, Levine R, Marto JA, Armstrong SA, Kentsis A.

Cancer Discov. 2018 Apr;8(4):478-497. doi: 10.1158/2159-8290.CD-17-1271. Epub 2018 Feb 5.

PMID:
29431698
13.

Peptidomimetic blockade of MYB in acute myeloid leukemia.

Ramaswamy K, Forbes L, Minuesa G, Gindin T, Brown F, Kharas MG, Krivtsov AV, Armstrong SA, Still E, de Stanchina E, Knoechel B, Koche R, Kentsis A.

Nat Commun. 2018 Jan 9;9(1):110. doi: 10.1038/s41467-017-02618-6.

14.

SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.

Mar BG, Chu SH, Kahn JD, Krivtsov AV, Koche R, Castellano CA, Kotlier JL, Zon RL, McConkey ME, Chabon J, Chappell R, Grauman PV, Hsieh JJ, Armstrong SA, Ebert BL.

Blood. 2017 Dec 14;130(24):2631-2641. doi: 10.1182/blood-2017-03-775569. Epub 2017 Oct 10.

15.

Erratum: PGBD5 promotes site-specific oncogenic mutations in human tumors.

Henssen AG, Koche R, Zhuang J, Jiang E, Reed C, Eisenberg A, Still E, MacArthur IC, Rodríguez-Fos E, Gonzalez S, Puiggròs M, Blackford AN, Mason CE, de Stanchina E, Gönen M, Emde AK, Shah M, Arora K, Reeves C, Socci ND, Perlman E, Antonescu CR, Roberts CWM, Steen H, Mullen E, Jackson SP, Torrents D, Weng Z, Armstrong SA, Kentsis A.

Nat Genet. 2017 Sep 27;49(10):1558. doi: 10.1038/ng1017-1558b. No abstract available.

PMID:
28951624
16.

miR-99 regulates normal and malignant hematopoietic stem cell self-renewal.

Khalaj M, Woolthuis CM, Hu W, Durham BH, Chu SH, Qamar S, Armstrong SA, Park CY.

J Exp Med. 2017 Jul 21. pii: jem.20161595. doi: 10.1084/jem.20161595. [Epub ahead of print]

17.

A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription.

Wang SP, Tang Z, Chen CW, Shimada M, Koche RP, Wang LH, Nakadai T, Chramiec A, Krivtsov AV, Armstrong SA, Roeder RG.

Mol Cell. 2017 Jul 20;67(2):308-321.e6. doi: 10.1016/j.molcel.2017.06.028.

18.

PGBD5 promotes site-specific oncogenic mutations in human tumors.

Henssen AG, Koche R, Zhuang J, Jiang E, Reed C, Eisenberg A, Still E, MacArthur IC, Rodríguez-Fos E, Gonzalez S, Puiggròs M, Blackford AN, Mason CE, de Stanchina E, Gönen M, Emde AK, Shah M, Arora K, Reeves C, Socci ND, Perlman E, Antonescu CR, Roberts CWM, Steen H, Mullen E, Jackson SP, Torrents D, Weng Z, Armstrong SA, Kentsis A.

Nat Genet. 2017 Jul;49(7):1005-1014. doi: 10.1038/ng.3866. Epub 2017 May 15. Erratum in: Nat Genet. 2017 Sep 27;49(10 ):1558.

19.

Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.

Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, Calvo-Vidal MN, Chou T, Chow A, Minuesa G, Park SM, Barlowe TS, Taggart J, Tivnan P, Deering RP, Chu LP, Kwon JA, Meydan C, Perales-Paton J, Arshi A, Gönen M, Famulare C, Patel M, Paietta E, Tallman MS, Lu Y, Glass J, Garret-Bakelman FE, Melnick A, Levine R, Al-Shahrour F, Järås M, Hacohen N, Hwang A, Garippa R, Lengner CJ, Armstrong SA, Cerchietti L, Cowley GS, Root D, Doench J, Leslie C, Ebert BL, Kharas MG.

Nat Genet. 2017 Jun;49(6):866-875. doi: 10.1038/ng.3854. Epub 2017 Apr 24.

20.

Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.

Remillard D, Buckley DL, Paulk J, Brien GL, Sonnett M, Seo HS, Dastjerdi S, Wühr M, Dhe-Paganon S, Armstrong SA, Bradner JE.

Angew Chem Int Ed Engl. 2017 May 15;56(21):5738-5743. doi: 10.1002/anie.201611281. Epub 2017 Apr 18.

21.

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.

Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J.

Science. 2017 Mar 24;355(6331):1324-1330. doi: 10.1126/science.aah6893.

22.

Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia.

Krivtsov AV, Hoshii T, Armstrong SA.

Cold Spring Harb Perspect Med. 2017 Nov 1;7(11). pii: a026658. doi: 10.1101/cshperspect.a026658. Review.

PMID:
28242784
23.

ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia.

Wan L, Wen H, Li Y, Lyu J, Xi Y, Hoshii T, Joseph JK, Wang X, Loh YE, Erb MA, Souza AL, Bradner JE, Shen L, Li W, Li H, Allis CD, Armstrong SA, Shi X.

Nature. 2017 Mar 9;543(7644):265-269. doi: 10.1038/nature21687. Epub 2017 Mar 1.

24.

Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis.

Valerio DG, Xu H, Chen CW, Hoshii T, Eisold ME, Delaney C, Cusan M, Deshpande AJ, Huang CH, Lujambio A, Zheng YG, Zuber J, Pandita TK, Lowe SW, Armstrong SA.

Cancer Res. 2017 Apr 1;77(7):1753-1762. doi: 10.1158/0008-5472.CAN-16-2374. Epub 2017 Feb 15.

25.

Discovery and Characterization of a Peptoid with Antifungal Activity against Cryptococcus neoformans.

Corson AE, Armstrong SA, Wright ME, McClelland EE, Bicker KL.

ACS Med Chem Lett. 2016 Oct 3;7(12):1139-1144. eCollection 2016 Dec 8.

26.

NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis.

Xu H, Valerio DG, Eisold ME, Sinha A, Koche RP, Hu W, Chen CW, Chu SH, Brien GL, Park CY, Hsieh JJ, Ernst P, Armstrong SA.

Cancer Cell. 2016 Dec 12;30(6):863-878. doi: 10.1016/j.ccell.2016.10.019. Epub 2016 Nov 23.

27.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

28.

Histone acetyltransferase activity of MOF is required for adult but not early fetal hematopoiesis in mice.

Valerio DG, Xu H, Eisold ME, Woolthuis CM, Pandita TK, Armstrong SA.

Blood. 2017 Jan 5;129(1):48-59. doi: 10.1182/blood-2016-05-714568. Epub 2016 Nov 8.

29.

Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus.

Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C.

Blood. 2017 Jan 19;129(3):319-323. doi: 10.1182/blood-2016-04-706978. Epub 2016 Nov 8.

30.

AACR Cancer Progress Report 2016.

Davidson NE, Armstrong SA, Coussens LM, Cruz-Correa MR, DeBerardinis RJ, Doroshow JH, Foti M, Hwu P, Kensler TW, Morrow M, Mulligan CG, Pao W, Platz EA, Smith TJ, Willman CL.

Clin Cancer Res. 2016 Oct 1;22 Suppl 19:S1-S137. No abstract available.

31.

Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.

Morgado-Palacin I, Day A, Murga M, Lafarga V, Anton ME, Tubbs A, Chen HT, Ergan A, Anderson R, Bhandoola A, Pike KG, Barlaam B, Cadogan E, Wang X, Pierce AJ, Hubbard C, Armstrong SA, Nussenzweig A, Fernandez-Capetillo O.

Sci Signal. 2016 Sep 13;9(445):ra91. doi: 10.1126/scisignal.aad8243.

32.

Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.

Kühn MW, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, Cusan M, Farnoud N, Mupo A, Grove C, Koche R, Bradner JE, de Stanchina E, Vassiliou GS, Hoshii T, Armstrong SA.

Cancer Discov. 2016 Oct;6(10):1166-1181. Epub 2016 Aug 17.

33.

Forward genetic screen of human transposase genomic rearrangements.

Henssen AG, Jiang E, Zhuang J, Pinello L, Socci ND, Koche R, Gonen M, Villasante CM, Armstrong SA, Bauer DE, Weng Z, Kentsis A.

BMC Genomics. 2016 Aug 4;17:548. doi: 10.1186/s12864-016-2877-x.

34.

Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.

Wang K, Sanchez-Martin M, Wang X, Knapp KM, Koche R, Vu L, Nahas MK, He J, Hadler M, Stein EM, Tallman MS, Donahue AL, Frampton GM, Lipson D, Roels S, Stephens PJ, Sanford EM, Brennan T, Otto GA, Yelensky R, Miller VA, Kharas MG, Levine RL, Ferrando A, Armstrong SA, Krivtsov AV.

Leukemia. 2017 Jan;31(1):151-158. doi: 10.1038/leu.2016.166. Epub 2016 Jun 13.

35.

Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.

Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, Krivtsov A, Armstrong SA, Palacino J, Buonamici S, Smith PG, Bradley RK, Abdel-Wahab O.

Nat Med. 2016 Jun 7;22(6):692. doi: 10.1038/nm0616-692d. No abstract available.

36.

Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status".

LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL.

Nat Med. 2016 Jun 7;22(6):578-9. doi: 10.1038/nm.4094. No abstract available.

PMID:
27270773
37.

The role of DOT1L in the maintenance of leukemia gene expression.

Wang X, Chen CW, Armstrong SA.

Curr Opin Genet Dev. 2016 Feb;36:68-72. doi: 10.1016/j.gde.2016.03.015. Epub 2016 May 3. Review.

PMID:
27151433
38.

Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.

Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, Krivtsov A, Armstrong SA, Palacino J, Buonamici S, Smith PG, Bradley RK, Abdel-Wahab O.

Nat Med. 2016 Jun;22(6):672-8. doi: 10.1038/nm.4097. Epub 2016 May 2. Erratum in: Nat Med. 2016 Jun 7;22(6):692.

39.

Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.

Brien GL, Valerio DG, Armstrong SA.

Cancer Cell. 2016 Apr 11;29(4):464-476. doi: 10.1016/j.ccell.2016.03.007. Review.

40.

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.

He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, Patel J, Krivstov A, Frampton GM, Young LE, Zhong S, Bailey M, White JR, Roels S, Deffenbaugh J, Fichtenholtz A, Brennan T, Rosenzweig M, Pelak K, Knapp KM, Brennan KW, Donahue AL, Young G, Garcia L, Beckstrom ST, Zhao M, White E, Banning V, Buell J, Iwanik K, Ross JS, Morosini D, Younes A, Hanash AM, Paietta E, Roberts K, Mullighan C, Dogan A, Armstrong SA, Mughal T, Vergilio JA, Labrecque E, Erlich R, Vietz C, Yelensky R, Stephens PJ, Miller VA, van den Brink MR, Otto GA, Lipson D, Levine RL.

Blood. 2016 Jun 16;127(24):3004-14. doi: 10.1182/blood-2015-08-664649. Epub 2016 Mar 10.

41.

MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.

Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM.

J Clin Invest. 2016 Apr 1;126(4):1438-50. doi: 10.1172/JCI80825. Epub 2016 Feb 29.

42.

Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.

Danis E, Yamauchi T, Echanique K, Zhang X, Haladyna JN, Riedel SS, Zhu N, Xie H, Orkin SH, Armstrong SA, Bernt KM, Neff T.

Cell Rep. 2016 Mar 1;14(8):1953-65. doi: 10.1016/j.celrep.2016.01.064. Epub 2016 Feb 18.

43.

MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C.

Zhu N, Chen M, Eng R, DeJong J, Sinha AU, Rahnamay NF, Koche R, Al-Shahrour F, Minehart JC, Chen CW, Deshpande AJ, Xu H, Chu SH, Ebert BL, Roeder RG, Armstrong SA.

J Clin Invest. 2016 Mar 1;126(3):997-1011. doi: 10.1172/JCI82978. Epub 2016 Feb 15.

44.

Predicting Marathon Time Using Exhaustive Graded Exercise Test in Marathon Runners.

Till ES, Armstrong SA, Harris G, Maloney S.

J Strength Cond Res. 2016 Feb;30(2):512-7. doi: 10.1519/JSC.0000000000001152.

PMID:
26815178
45.

Editorial overview: Differentiation and disease.

Armstrong SA, Rape M.

Curr Opin Cell Biol. 2015 Dec;37:v-vi. doi: 10.1016/j.ceb.2015.11.001. Epub 2015 Nov 25. No abstract available.

PMID:
26626586
46.

Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.

Cai SF, Chen CW, Armstrong SA.

Mol Cell. 2015 Nov 19;60(4):561-70. doi: 10.1016/j.molcel.2015.10.042. Review.

47.

JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.

Chen M, Zhu N, Liu X, Laurent B, Tang Z, Eng R, Shi Y, Armstrong SA, Roeder RG.

Genes Dev. 2015 Oct 15;29(20):2123-39. doi: 10.1101/gad.267278.115.

48.

A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence.

Brien GL, Healy E, Jerman E, Conway E, Fadda E, O'Donovan D, Krivtsov AV, Rice AM, Kearney CJ, Flaus A, McDade SS, Martin SJ, McLysaght A, O'Connell DJ, Armstrong SA, Bracken AP.

Genes Dev. 2015 Nov 1;29(21):2231-43. doi: 10.1101/gad.267930.115. Epub 2015 Oct 22.

49.

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.

Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T, Heidel FH.

Leukemia. 2016 May;30(5):1220-1225. doi: 10.1038/leu.2015.292. Epub 2015 Oct 21. No abstract available.

50.

The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.

Chen S, Yang Z, Wilkinson AW, Deshpande AJ, Sidoli S, Krajewski K, Strahl BD, Garcia BA, Armstrong SA, Patel DJ, Gozani O.

Mol Cell. 2015 Oct 15;60(2):319-27. doi: 10.1016/j.molcel.2015.08.019. Epub 2015 Oct 1.

Supplemental Content

Loading ...
Support Center